Abstract
A multi-central clinical trial was conducted to assess the effect of TKD-36 (Moku-boi-to)on chronic heart failure in dogs. TKD-36 (75, 150 or 300 mg/kg/day, divided b. i. d., p. o.) or placebo were administered for 4 weeks to dogs showing signs of chronic heart failure. Overall assessment and various clinical evaluation of clinical symptoms in dogs treated with TKD-36 (150 and 300 mg/kg/day) were excellent compared to that in dogs treated with the placebo. But the dose of 75 mg/kg/day of TKD-36 did not improve any clinical signs of heart failure as same as the placebo group. No adverse reactions attributable to TKD-36 administration were observed, confirming its safety in this species. Based on efficacy, safety and overall assessment analyses, the optimal dosage of TKD-36 is from 150 to 300 mg/kg/day.
These results clearly indicate that TKD-36 is an excellent drug for a treatment of the chronic heart failure in dogs.
